TD 1439

Drug Profile

TD 1439

Alternative Names: TD-1439

Latest Information Update: 07 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Theravance Biopharma
  • Class Small molecules
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 27 Feb 2017 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers released by Theravance
  • 27 Feb 2017 Theravance completes a phase I single ascending dose trial in Cardiovascular and kidney disorders (In adults, In volunteers) in USA (NCT02903095)
  • 01 Nov 2016 Phase-I clinical trials in Cardiovascular disorders (In adults, In the elderly, In volunteers) in USA (PO) (NCT02954263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top